Biotech RadarJobs updated

COMPANY

Sarfez Pharmaceuticals

HQ: Vienna, VA source · sarfez.com ↗ · Southeast

Clinical Phase 3

Location: Vienna, VA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Heart Failure Edema Pulmonary Congestion Fluid Overload Hypertension Body Weight Changes Overactive Bladder Incontinence PK/PD Congestive Heart Failure Chronic Kidney Diseases Food-drug Interaction torsemide

11Trials (company is sponsor)3NIH grants

Timeline

  1. Trial start Phase 3: Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects source ↗
  2. Trial start Phase 3: Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone source ↗
  3. Trial start Phase 3: A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects source ↗
  4. Trial start Phase 3: A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Di source ↗
  5. Trial start Phase 4: Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure source ↗
  6. Trial start Phase 4: A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs source ↗
  7. Trial start Phase 2: Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal source ↗
  8. Trial start Phase 2: Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder source ↗
  9. Trial start Phase 1: Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide source ↗
  10. Trial start Phase 1: A Food Effect Study of 60mg ER Torsemide source ↗
  11. Trial start Phase 1: Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects source ↗

Clinical trials (lead sponsor) 11

RecordTitlePhaseStatusStartPrimary completion
NCT06995144Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart FailurePhase 4Withdrawn2025-05Sep 16, 2026 (actual)
NCT07223502A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney DiseasePhase 3WithdrawnMay 1, 2025Sep 17, 2026 (actual)
NCT06708611A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 HrsPhase 4WithdrawnJan 15, 2025Mar 25, 2025 (actual)
NCT06176794Immediate Release Torsemide Versus Extended Release Torsemide After Salty MealPhase 2WithdrawnNov 15, 2024Mar 25, 2025 (actual)
NCT03509545Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg FurosemidePhase 1TerminatedJun 30, 2021Jun 30, 2022 (actual)
NCT06206512Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive BladderPhase 2CompletedJun 15, 2024Nov 17, 2025 (actual)
NCT07046975Bioavailability and Bioequivalence Study of Extended Release Torsemide and SpironolactonePhase 3CompletedJun 15, 2025Feb 28, 2026 (actual)
NCT07015671Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy SubjectsPhase 3CompletedJul 1, 2025Dec 30, 2025 (actual)
NCT07043634A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult SubjectsPhase 3CompletedJun 15, 2025Dec 30, 2025 (actual)
NCT03214874Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy SubjectsPhase 1CompletedJun 19, 2017Jul 20, 2017 (actual)
NCT03215875A Food Effect Study of 60mg ER TorsemidePhase 1CompletedOct 17, 2017Mar 31, 2018 (actual)

NIH awards 3

Annual award amounts. Total $2.3M.

Feedback